Christer Fåhraeus

Christer Fåhraeus is a declared insider at 3 companies (board member); the most frequent names are CellaVision AB, EQL Pharma AB and OssDsign AB. We count 54 filings; the first trade dates from 19 May 2017 and the latest from 9 June 2026.

The open-market side counts 33 purchases for €10.5M alongside 15 sales for €20.0M. The net balance comes to €9.5M on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. In 2026 alone, the filings show 9 purchases and no sales.

Half of the purchases are above €44k and half below. Measured against the company's value, the median purchase equals 0.068% of market capitalisation, across 7 purchases where it is known. 10 out of 31 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster. Ninety days after publication, 10 purchases show a median change of +14.5%, with the price up in 60% of them. This is a record of the past, not a forecast.

On 10 June 2026 came the latest disclosure, an open-market purchase for €385k in CellaVision AB. Between a trade and the moment it shows up on Finansinspektionen, the median delay is 2 days. For comparison, MAR article 19 gives managers three business days to notify a trade. Source: insider filings from Finansinspektionen. Past trades are no guide to future returns.